Conexeu Sciences Inc.

CNXU

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.89

−$0.54 · -5.73%

Aug 21, 4:00 PM ET

Historical prices · Market data may be delayed.

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $8.89

$8.68$10.2909

52-week range

Current $8.89

$6.85$18.79

Open: $9.42
Previous close: $9.43
Volume: 403.66K
Market cap: 237.88M USD
50-day average: $9.7068; -8.41% below average
200-day average: $10.70; -16.92% below average

Earnings

EPS beat rate: 0%; 0 beats, 0 misses, 1 met estimate
Average EPS surprise: 0.00%; 1 comparable report
Latest EPS result: -0.11; Estimate -0.11 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$20.00

124.97% upside

Past 12 months12-month forecastHigh $20.00Average $20.00Low $20.00

CNXU news

globenewswire.comAug 18, 2026

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform

Read source

prnewswire.comJul 15, 2026

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

/PRNewswire/ -- Equity Insider News Commentary - Every so often, a wave of demand in one corner of medicine spills over and creates an entirely new market next

Read source

globenewswire.comJul 14, 2026

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

Read source

globenewswire.comJul 7, 2026

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence…

Read source

globenewswire.comJun 25, 2026

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

Read source

seekingalpha.comJun 24, 2026

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance…

Read source